BACKGROUND: The objective of this study was to determine whether hatha yoga is an efficacious adjunctive intervention for individuals with continued depressive symptoms despite antidepressant treatment. METHOD: We conducted a randomized controlled trial of weekly yoga classes (n = 63) v. health education classes (Healthy Living Workshop; HLW; n = 59) in individuals with elevated depression symptoms and antidepressant medication use. HLW served as an attention-control group. The intervention period was 10 weeks, with follow-up assessments 3 and 6 months afterwards. The primary outcome was depression symptom severity assessed by blind rater at 10 weeks. Secondary outcomes included depression symptoms over the entire intervention and follow-up periods, social and role functioning, general health perceptions, pain, and physical functioning. RESULTS: At 10 weeks, we did not find a statistically significant difference between groups in depression symptoms (b = -0.82, s.e. = 0.88, p = 0.36). However, over the entire intervention and follow-up period, when controlling for baseline, yoga participants showed lower levels of depression than HLW participants (b = -1.38, s.e. = 0.57, p = 0.02). At 6-month follow-up, 51% of yoga participants demonstrated a response (⩾50% reduction in depression symptoms) compared with 31% of HLW participants (odds ratio = 2.31; p = 0.04). Yoga participants showed significantly better social and role functioning and general health perceptions over time. CONCLUSIONS: Although we did not see a difference in depression symptoms at the end of the intervention period, yoga participants showed fewer depression symptoms over the entire follow-up period. Benefits of yoga may accumulate over time.
RCT Entities:
BACKGROUND: The objective of this study was to determine whether hatha yoga is an efficacious adjunctive intervention for individuals with continued depressive symptoms despite antidepressant treatment. METHOD: We conducted a randomized controlled trial of weekly yoga classes (n = 63) v. health education classes (Healthy Living Workshop; HLW; n = 59) in individuals with elevated depression symptoms and antidepressant medication use. HLW served as an attention-control group. The intervention period was 10 weeks, with follow-up assessments 3 and 6 months afterwards. The primary outcome was depression symptom severity assessed by blind rater at 10 weeks. Secondary outcomes included depression symptoms over the entire intervention and follow-up periods, social and role functioning, general health perceptions, pain, and physical functioning. RESULTS: At 10 weeks, we did not find a statistically significant difference between groups in depression symptoms (b = -0.82, s.e. = 0.88, p = 0.36). However, over the entire intervention and follow-up period, when controlling for baseline, yoga participants showed lower levels of depression than HLW participants (b = -1.38, s.e. = 0.57, p = 0.02). At 6-month follow-up, 51% of yoga participants demonstrated a response (⩾50% reduction in depression symptoms) compared with 31% of HLW participants (odds ratio = 2.31; p = 0.04). Yoga participants showed significantly better social and role functioning and general health perceptions over time. CONCLUSIONS: Although we did not see a difference in depression symptoms at the end of the intervention period, yoga participants showed fewer depression symptoms over the entire follow-up period. Benefits of yoga may accumulate over time.
Authors: Lisa A Uebelacker; Geoffrey Tremont; Gary Epstein-Lubow; Brandon A Gaudiano; Tom Gillette; Zornitsa Kalibatseva; Ivan W Miller Journal: Behav Modif Date: 2010-04-16
Authors: Ana M Abrantes; Erika Litvin Bloom; David R Strong; Deborah Riebe; Bess H Marcus; Julie Desaulniers; Kathryn Fokas; Richard A Brown Journal: Nicotine Tob Res Date: 2014-05-08 Impact factor: 4.244
Authors: A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: Lisa A Uebelacker; Gary Epstein-Lubow; Brandon A Gaudiano; Geoffrey Tremont; Cynthia L Battle; Ivan W Miller Journal: J Psychiatr Pract Date: 2010-01 Impact factor: 1.325
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Ana M Abrantes; Nicole McLaughlin; Benjamin D Greenberg; David R Strong; Deborah Riebe; Maria Mancebo; Steven Rasmussen; Julie Desaulniers; Richard A Brown Journal: Ment Health Phys Act Date: 2012-06-30
Authors: Lisa A Uebelacker; Donnell Van Noppen; Geoffrey Tremont; Genie Bailey; Ana Abrantes; Michael Stein Journal: J Subst Abuse Treat Date: 2019-07-24
Authors: Lisa A Uebelacker; Morganne Kraines; Monica K Broughton; Geoffrey Tremont; L Tom Gillette; Gary Epstein-Lubow; Ana M Abrantes; Cynthia Battle; Ivan W Miller Journal: Complement Ther Med Date: 2017-06-27 Impact factor: 2.446
Authors: Lisa A Uebelacker; Lauren M Weinstock; Cynthia L Battle; Ana M Abrantes; Ivan W Miller Journal: J Affect Disord Date: 2018-06-02 Impact factor: 4.839
Authors: Michael D Stein; Celeste M Caviness; Emily F Morse; Kristin R Grimone; Daniel Audet; Debra S Herman; Ethan Moitra; Bradley J Anderson Journal: Addiction Date: 2017-10-16 Impact factor: 6.526
Authors: Crystal L Park; Lucy Finkelstein-Fox; Erik J Groessl; A Rani Elwy; Sharon Y Lee Journal: Complement Ther Med Date: 2020-02-25 Impact factor: 2.446
Authors: Nicole R Nugent; Leslie Brick; Michael F Armey; Audrey R Tyrka; Kathryn K Ridout; Lisa A Uebelacker Journal: Behav Med Date: 2019-05-29 Impact factor: 3.104